In stark contrast to the consistent findings from the vast observational data, the highest level of clinical evidence, which is derived from meta-analyses of large-scale RCTs, has thus far failed to demonstrate a significant association between SGLT2 inhibitor treatment and a reduced risk of dementia. Here, SLC5A2 is linked to dementia.